A comparative study of seeding techniques and three-dimensional matrices for mesenchymal cell attachment.

Mesenchymal stem cells (MSCs) offer significant potential as a cell source in tissue-engineering applications because of their multipotent ability. The objective of this study was to evaluate the behaviour of MSCs during the seeding phase, using four different seeding techniques (spinner flask, custom vacuum system combined with a perfused bioreactor or with an orbital shaker, and orbital shaker) with four different scaffold materials [polyglycolic acid, poly(lactic acid), calcium phosphate and chitosan-hyaluronic acid]. Scaffolds were selected for their structural and/or chemical similarity with bone or cartilage, and characterized via scanning electron microscopy (SEM) and measurement of fluid retention.

Shear-induced cyclooxygenase-2 via a JNK2/c-Jun-dependent pathway regulates prostaglandin receptor expression in chondrocytic cells.

Using cDNA microarrays coupled with bioinformatics tools, we elucidated a signaling cascade regulating cyclooxygenase-2 (COX-2), a pivotal pro-inflammatory enzyme expressed in rheumatic and osteoarthritic, but not normal, cartilage. Exposure of T/C-28a2 chondrocytic cells to fluid shear results in co-regulation of c-Jun N-terminal kinase2 (JNK2), c-Jun, and COX-2 as well as concomitant downstream expression of prostaglandin receptors EP2 and EP3a1. JNK2 transcript inhibition abrogated shear-induced COX-2, EP2, and EP3a1 mRNA up-regulation as well as c-Jun phosphorylation.

Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.

This study was undertaken to compare the platelet binding characteristics and anti-platelet efficacy of a nonpeptide glycoprotein IIb/IIIa antagonist roxifiban with orbofiban in static and dynamic adhesion and aggregation assays. The results indicate that roxifiban binds with higher affinity to glycoprotein IIb/IIIa receptors and exhibits slower dissociation rates than orbofiban. Furthermore, the platelet inhibitory effects of roxifiban, but not orbofiban, were unaffected by changes in plasma calcium concentrations.